SESSION TITLE: Medical Student/Resident Critical Care Posters SESSION TYPE: Med Student/Res Case Rep Postr PRESENTED ON: October 18-21, 2020 INTRODUCTION: Hemophagocytic lymphohistiocytosis (HLH) is characterized by pathologic immune activation leading to multiorgan failure. In sepsis, it presents due to an infectious trigger resulting in overwhelming cytokine release. This is known as sepsis-HLH overlap syndrome (SHLHOS)(1). We present a case of septic shock with HLH overlap successfully treated with therapeutic plasma exchange (TPE). CASE PRESENTATION: A 61 year old male was admitted for obstructive uropathy. He was febrile to 102.5F, HR was 133 bpm and BP 141/93 mmHg. He had a leukocytosis of 21.2 k/uL, lactic acidosis and procalcitonin of 49.2 ng/mL. Imaging showed an obstructive 4.1 mm ureteral stone with hydronephrosis. Broad spectrum antibiotics were initiated and a nephrostomy tube was placed. Despite fluids, hemodynamics declined and he required supratherapeutic doses of 5 different vasopressors. He had shock liver, progressive acidosis and oliguric renal failure requiring continuous renal replacement therapy. Blood cultures showed gram negative rods and procalcitonin remained >200 ng/L. Due to a lack of improvement, there was concern for immune dysregulation. Ferritin was elevated at 21,197 ng/ml, IL-2 receptor alpha was 4,398 u/ml, LDH was >2,250 U/L and IL-6 level was elevated at 44.5 pg/m. This, along with anemia and thrombocytopenia was supportive of a diagnosis of SHLHOS. Due to continued declining status, and a relative contraindication of pulse steroids in active bacteremia, TPE with fresh frozen plasma was initiated. After two sessions he was weaned off all vasopressors over 72 hours. His ferritin improved to 1,700 ng/ml, procalcitonin decreased to 29 ng/L and lactic acidosis resolved. He was extubated and antibiotics were tailored to his E. Coli bacteremia. DISCUSSION: Sepsis-HLH overlap syndrome is under recognized and undertreated. Hemophagocytosis can be present in a large number of sepsis patients. Biomarkers including IL-6, IL-2 receptor alpha, IFN-gamma and ferritin may be useful in identifying these patients early. Higher levels of ferritin, typically >10,000 ng/mL have been associated with HLH. These elevated biomarkers have correlation with clinical status as well as response to therapy and mortality(2). The target of therapy in SHLHOS is to suppress the immune response which includes steroids, anakinra and immunoglobulins. TPE has the potential to improve hemodynamics and survival by removing inflammatory cytokines and replacing protective factors and may represent an effective, yet underutilized modality of therapy (3). It is important to recognize sepsis patients who are at high risk of developing SHLHOS in order to provide timely and potentially life-saving intervention. TPE may be beneficial in SHLHOS resulting in improved hemodynamics. CONCLUSIONS: Therapeutic plasma exchange may be beneficial in sepsis-HLH overlap syndrome resulting in improved hemodynamics. Reference #1: Weitzman S. Approach to hemophagocytic syndromes. Hematology Am Soc Hematol Educ Program 2011;2011:178–83 Reference #2: Kuwata K, Yamada S, Kinuwaki E, Naito M, Mitsuya H. Peripheral hemophagocytosis: An early indicator of advanced systemic inflammatory response syndrome/hemophagocytic syndrome. Shock. 2006 Apr;25(4):344-50 Reference #3: Demirkol D, Yildizdas D, Bayrakci B, et al. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?. Crit Care. 2012;16(2):R52. Published 2012 Dec 12 DISCLOSURES: No relevant relationships by Muhammad Ibrar Islam, source=Web Response No relevant relationships by Paul Marik, source=Web Response No relevant relationships by Mit Patel, source=Web Response No relevant relationships by Nina Swiacki, source=Web Response